AVE 8923Alternative Names: AVE 8923A; AVE8923
Latest Information Update: 18 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Antiasthmatics
- Mechanism of Action Beta tryptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 13 Feb 2007 Phase-I clinical trials in Asthma (unspecified route)
- 16 Sep 2005 This programme is still in active development